News Related to Endogenous Hypercortisolism

Related coverage linked through entity extraction aliases.

Corcept Loses Patent Appeal Against Teva Over Korlym Generic

Feb 20, 2026

The U.S. Court of Appeals for the Federal Circuit ruled that Teva Pharmaceuticals did not infringe Corcept Therapeutics' patents for methods of safely co-administering Korlym with CYP3A4 inhibitors, affirming a 2023 district court verdict.

FDA Issues Complete Response Letter for Corcept's Relacorilant in Hypercortisolism

Sep 11, 2025

The FDA issued a Complete Response Letter for Corcept's relacorilant as a treatment for hypertension secondary to hypercortisolism, requesting additional evidence of effectiveness despite acknowledging positive trial results.